Isobe Yoshiaki, Kurimoto Ayumu, Tobe Masanori, Hashimoto Kazuki, Nakamura Tomoaki, Norimura Kei, Ogita Haruhisa, Takaku Haruo
Chemistry Research Laboratories and Discovery Research Laboratories II, Dainippon Sumitomo Pharmaceuticals Company Ltd., 1-98, Kasugade Naka, 3-chome, Konohana-ku, Osaka 554-0022, Japan.
J Med Chem. 2006 Mar 23;49(6):2088-95. doi: 10.1021/jm051089s.
Recently we reported the adenine derivatives 3a-d as novel interferon (IFN) inducers. In the present study, we conducted a detailed structure-activity relationship study of analogues of 3a-d with respect to their IFN-inducing activity, mainly focusing on the N(9)-position of the adenine. From this study, we found that introduction of the 3-pyridylmethyl moiety was effective to increase in vitro activity, and compound 9ae was identified as being the most potent IFN inducer. This compound gave a minimum effective concentration (MEC) of 3 nM, which is comparable with that of R-848, a second generation IFN inducer. Compound 9ae also demonstrated potent IFN-inducing activity at a dose of 0.1 mg/kg by oral administration in mice. Furthermore, compound 9ae induced IFN in monkeys in a dose dependent manner, with a potency superior to that of R-848. In addition, 9ae did not cause emesis in ferrets even at a dose of 30 mg/kg. In this study the maximum plasma concentration of 9ae was 1019 ng/mL (ca. 3.1 microM), which was approximately 1000-fold higher than the MEC value. Therefore, with respect to both the efficacy and the safety margin, compound 9ae (SM-276001) is considered to be a promising compound as an orally active IFN inducer.
最近我们报道了腺嘌呤衍生物3a-d作为新型干扰素(IFN)诱导剂。在本研究中,我们针对3a-d类似物的IFN诱导活性进行了详细的构效关系研究,主要聚焦于腺嘌呤的N(9)位。通过这项研究,我们发现引入3-吡啶基甲基部分可有效提高体外活性,化合物9ae被确定为最有效的IFN诱导剂。该化合物的最小有效浓度(MEC)为3 nM,与第二代IFN诱导剂R-848相当。化合物9ae经小鼠口服给药,剂量为0.1 mg/kg时也表现出强大的IFN诱导活性。此外,化合物9ae在猴子体内以剂量依赖性方式诱导IFN,效力优于R-848。另外,即使剂量为30 mg/kg,9ae在雪貂中也不会引起呕吐。在本研究中,9ae的最大血浆浓度为1019 ng/mL(约3.1 microM),比MEC值高约1000倍。因此, 就疗效和安全范围而言,化合物9ae(SM-276001)被认为是一种有前景的口服活性IFN诱导剂。